Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Fujifilm will build liposome drug plant
by Jean-François Tremblay
March 5, 2018
| A version of this story appeared in
Volume 96, Issue 10
Fujifilm will spend $37 million to build a liposome drug plant in Toyoma, Japan. The facility will support Fujifilm’s effort to develop and launch liposome drugs—in particular, an anticancer agent that Fujifilm plans to start testing in the U.S. this year. In liposome drugs, active substances are contained in artificial vesicles made from organic materials that closely resemble cells and membranes. The method may improve delivery of anticancer agents to the targeted tumor, Fujifilm says.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter